Very rarely. Myocarditis is proven, cardiomyopathy is not

The exact condition named, cardiomyopathy, is a chronic heart muscle disease. The vaccine-linked harm that is well documented is acute myocarditis, mainly after mRNA vaccines. It is uncommon overall, more frequent in young men, and usually resolves with little treatment. Follow-up studies have found that most patients recover normal heart function. A few have lingering MRI abnormalities, and researchers are still tracking long-term outcomes. There is no solid evidence that the vaccines cause chronic cardiomyopathy, so this answer is 'yes' only for the related, rare myocarditis. The risk of heart inflammation from COVID-19 infection is generally higher than from the vaccine.

• Myocarditis and pericarditis after mRNA vaccines (Pfizer, Moderna) is an established, rare side effect, seen in surveillance data from many countries.
• The highest risk is in adolescent and young adult males, typically within about a week of the second dose.
• Most cases are mild and recover within days to weeks. Some follow-up MRI studies show residual scarring in a minority of people, and long-term significance is still being studied.
• No good evidence shows the vaccines cause chronic cardiomyopathy (a lasting weakening of the heart muscle) in a meaningful number of people.
• COVID-19 infection itself carries a higher risk of myocarditis and other heart complications than vaccination, including in young males.

The established vaccine-associated harm is myocarditis, rather than a demonstrated general increase in chronic cardiomyopathy. Follow-up studies show generally favorable clinical outcomes, but persistent heart-muscle injury in some patients means it would also be incorrect to describe every case as temporary or harmless. The frequency category here describes myocarditis/pericarditis after the 2023–2024 formulations overall, not a measured rate of lasting cardiomyopathy; rates are higher in certain groups and with some earlier vaccine schedules.

• Myocarditis is inflammation of the heart muscle; it is not automatically a diagnosis of chronic cardiomyopathy.
• Risk varies by age, sex, vaccine product and dose, with young males most affected.
• Some affected patients have persistent MRI evidence of myocardial injury, whose long-term clinical significance remains uncertain.
• A French study of 558 patients hospitalized with postvaccination myocarditis found fewer serious cardiovascular outcomes over 18 months than with conventional myocarditis, although some required ongoing care.
• COVID infection generally carries greater myocarditis risk, but a study of 2020–2021 vaccinations found higher risk after Moderna's second dose than after infection in men younger than 40.

1. fda.gov
2. jamanetwork.com
3. pubmed.ncbi.nlm.nih.gov
4. jamanetwork.com
5. fda.gov
6. pubmed.ncbi.nlm.nih.gov
7. openheart.bmj.com
8. pmc.ncbi.nlm.nih.gov

While COVID-19 vaccines do not typically cause classical chronic dilated cardiomyopathy, they are linked to acute myocarditis, which is clinically classified as an inflammatory cardiomyopathy. Global health surveillance identified that mRNA vaccines (Pfizer-BioNTech and Moderna) carry a very rare risk of heart muscle inflammation, concentrated heavily among adolescent and young adult men shortly after the second dose. In the overwhelming majority of cases, the condition is mild and responds well to rest and anti-inflammatory treatment, with patients recovering normal heart function without lasting damage. By comparison, getting infected with COVID-19 carries a substantially higher risk of cardiac injury, severe myocarditis, and long-term heart dysfunction across all age groups.

• mRNA COVID-19 vaccines carry a recognized, very rare risk of acute myocarditis (heart muscle inflammation) and pericarditis.
• The risk is highest in adolescent and young adult males after the second dose, occurring in roughly 1 in 10,000 to 1 in 25,000 in that demographic.
• Overall incidence across the entire vaccinated population is estimated at roughly 1 to 5 cases per 100,000 people.
• Most vaccine-associated myocarditis cases are mild, resolve rapidly with standard care, and rarely progress to chronic cardiomyopathy.
• Infection with the SARS-CoV-2 virus carries a significantly higher risk of myocarditis, severe heart injury, and chronic cardiomyopathy than the vaccine.

1. vaccinesafety.edu
2. yalemedicine.org
3. youtube.com
4. yale.edu
5. fda.gov
6. ahajournals.org
7. nih.gov
8. cdc.gov

Scientific evidence confirms that mRNA COVID-19 vaccines can very rarely cause myocarditis, an inflammation of the heart muscle. This side effect is most commonly observed in adolescent and young adult males, typically after the second vaccine dose. The rate is extremely low, with studies reporting about 12.6 cases per million second doses in the 12-39 age group. While myocarditis can sometimes progress to cardiomyopathy (a chronic disease of the heart muscle), the evidence does not show a direct link between the COVID-19 vaccine and cardiomyopathy. Most cases of vaccine-associated myocarditis resolve with minimal or no long-term damage, especially if managed promptly. The risk of myocarditis and cardiomyopathy from COVID-19 infection itself is significantly higher than from vaccination.

• Myocarditis is a recognized rare side effect of mRNA COVID-19 vaccines, particularly in males aged 12-29 years after the second dose.
• The rate is about 12.6 cases per million second doses in individuals aged 12-39.
• Most cases of vaccine-associated myocarditis resolve with minimal or no long-term damage, but some may progress to complications like cardiomyopathy if untreated.
• COVID-19 infection itself carries a higher risk of myocarditis and cardiomyopathy than the vaccine.
• No direct evidence links the COVID-19 vaccine to cardiomyopathy, but myocarditis can lead to cardiomyopathy in some cases.

1. Myocarditis following COVID‐19 vaccine - PMC - NIH pmc.ncbi.nlm.nih.gov
2. Stanford Medicine study shows why mRNA COVID-19 vaccine can cause myocarditis med.stanford.edu
3. Systematic Review: The Impact of COVID-19 Vaccination on Myocarditis Risk and Recovery - PMC pmc.ncbi.nlm.nih.gov
4. Pfizer Shares Available Analyses of Myocarditis and ... pfizer.com
5. COVID-19 Vaccination-Induced Cardiomyopathy Requiring ... pmc.ncbi.nlm.nih.gov
6. Myocarditis With COVID-19 mRNA Vaccines | Circulation ahajournals.org
7. Cardiovascular Assessment up to One Year After COVID-19 Vaccine–Associated Myocarditis | Circulation ahajournals.org
8. Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia | npj Vaccines nature.com